JPS62292800A - 生物活性を有する金属タンパク質複合体およびその製法 - Google Patents
生物活性を有する金属タンパク質複合体およびその製法Info
- Publication number
- JPS62292800A JPS62292800A JP62137600A JP13760087A JPS62292800A JP S62292800 A JPS62292800 A JP S62292800A JP 62137600 A JP62137600 A JP 62137600A JP 13760087 A JP13760087 A JP 13760087A JP S62292800 A JPS62292800 A JP S62292800A
- Authority
- JP
- Japan
- Prior art keywords
- complex
- metalloprotein
- albumin
- protein
- antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000002184 metal Substances 0.000 title claims description 16
- 229910052751 metal Inorganic materials 0.000 title claims description 16
- 238000004519 manufacturing process Methods 0.000 title claims description 11
- 102000004169 proteins and genes Human genes 0.000 title claims description 10
- 108090000623 proteins and genes Proteins 0.000 title claims description 10
- 239000002131 composite material Substances 0.000 title 1
- 102000010750 Metalloproteins Human genes 0.000 claims description 26
- 108010063312 Metalloproteins Proteins 0.000 claims description 26
- 230000004071 biological effect Effects 0.000 claims description 12
- 102000006410 Apoproteins Human genes 0.000 claims description 11
- 108010083590 Apoproteins Proteins 0.000 claims description 11
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 claims description 11
- 102000008100 Human Serum Albumin Human genes 0.000 claims description 8
- 108091006905 Human Serum Albumin Proteins 0.000 claims description 8
- 150000002739 metals Chemical class 0.000 claims description 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 8
- 239000011701 zinc Substances 0.000 claims description 8
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 239000003431 cross linking reagent Substances 0.000 claims description 6
- SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 5
- 239000012634 fragment Substances 0.000 claims description 5
- TVZPLCNGKSPOJA-UHFFFAOYSA-N copper zinc Chemical compound [Cu].[Zn] TVZPLCNGKSPOJA-UHFFFAOYSA-N 0.000 claims description 4
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 3
- FMJUDUJLTNVWCH-UHFFFAOYSA-N 2-ethoxy-3-(4-hydroxyphenyl)propanoic acid Chemical compound CCOC(C(O)=O)CC1=CC=C(O)C=C1 FMJUDUJLTNVWCH-UHFFFAOYSA-N 0.000 claims description 2
- 150000001718 carbodiimides Chemical class 0.000 claims description 2
- MGNCLNQXLYJVJD-UHFFFAOYSA-N cyanuric chloride Chemical compound ClC1=NC(Cl)=NC(Cl)=N1 MGNCLNQXLYJVJD-UHFFFAOYSA-N 0.000 claims description 2
- 150000002463 imidates Chemical class 0.000 claims description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 5
- 150000001413 amino acids Chemical group 0.000 claims 5
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 3
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 230000001747 exhibiting effect Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 8
- 238000000034 method Methods 0.000 description 8
- 238000000502 dialysis Methods 0.000 description 6
- 102000009027 Albumins Human genes 0.000 description 5
- 108010088751 Albumins Proteins 0.000 description 5
- 239000004471 Glycine Substances 0.000 description 5
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 229910052725 zinc Inorganic materials 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 4
- -1 copper Chemical class 0.000 description 4
- 229910052802 copper Inorganic materials 0.000 description 4
- 239000010949 copper Substances 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide Chemical compound CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 102000014914 Carrier Proteins Human genes 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 239000002738 chelating agent Substances 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 230000009849 deactivation Effects 0.000 description 2
- 239000000539 dimer Substances 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 229910052760 oxygen Inorganic materials 0.000 description 2
- 239000001301 oxygen Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000000108 ultra-filtration Methods 0.000 description 2
- 229920000936 Agarose Polymers 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 229910017518 Cu Zn Inorganic materials 0.000 description 1
- 229910017752 Cu-Zn Inorganic materials 0.000 description 1
- 229910017943 Cu—Zn Inorganic materials 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 241001674048 Phthiraptera Species 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 102000008221 Superoxide Dismutase-1 Human genes 0.000 description 1
- 108010021188 Superoxide Dismutase-1 Proteins 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 229940045799 anthracyclines and related substance Drugs 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 238000004676 ballistic electron emission microscopy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- OSQPUMRCKZAIOZ-UHFFFAOYSA-N carbon dioxide;ethanol Chemical compound CCO.O=C=O OSQPUMRCKZAIOZ-UHFFFAOYSA-N 0.000 description 1
- 239000013043 chemical agent Substances 0.000 description 1
- 239000007805 chemical reaction reactant Substances 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- 239000010941 cobalt Substances 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 231100000599 cytotoxic agent Toxicity 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000002270 exclusion chromatography Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002808 molecular sieve Substances 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000012064 sodium phosphate buffer Substances 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/0004—Oxidoreductases (1.)
- C12N9/0089—Oxidoreductases (1.) acting on superoxide as acceptor (1.15)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
- C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
- C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Toxicology (AREA)
- Analytical Chemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB8613315A GB2191200B (en) | 1986-06-02 | 1986-06-02 | Process for preparing conjugates of metalloproteins and novel derivatives thereof |
| GB8613315 | 1986-06-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPS62292800A true JPS62292800A (ja) | 1987-12-19 |
Family
ID=10598769
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP62137600A Pending JPS62292800A (ja) | 1986-06-02 | 1987-05-29 | 生物活性を有する金属タンパク質複合体およびその製法 |
Country Status (10)
| Country | Link |
|---|---|
| JP (1) | JPS62292800A (da) |
| BE (1) | BE1002130A3 (da) |
| CH (1) | CH674939A5 (da) |
| DE (1) | DE3718476A1 (da) |
| DK (1) | DK280187A (da) |
| ES (1) | ES2004734A6 (da) |
| FR (1) | FR2603287B1 (da) |
| GB (1) | GB2191200B (da) |
| IT (1) | IT1207805B (da) |
| NL (1) | NL8701254A (da) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1317895B1 (it) * | 2000-08-10 | 2003-07-15 | Univ Napoli Federico Ii | Pseudo-metalloproteine, loro preparazione e loro uso. |
| MX354530B (es) * | 2013-02-27 | 2018-02-19 | Univ Autonoma Del Estado De Morelos | Composiciones que comprenden immp para coadyuvar al desarrollo, crecimiento y mejora de los parámetros productivos de animales de interés zootécnico, y uso de las mismas. |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA1168150A (en) * | 1981-12-18 | 1984-05-29 | The Governors Of The University Of Alberta | Targeting conjugates of albumin and therapeutic agents |
-
1986
- 1986-06-02 GB GB8613315A patent/GB2191200B/en not_active Expired - Fee Related
-
1987
- 1987-05-25 CH CH2040/87A patent/CH674939A5/fr not_active IP Right Cessation
- 1987-05-26 NL NL8701254A patent/NL8701254A/nl not_active Application Discontinuation
- 1987-05-29 ES ES8701587A patent/ES2004734A6/es not_active Expired
- 1987-05-29 JP JP62137600A patent/JPS62292800A/ja active Pending
- 1987-06-01 FR FR878707639A patent/FR2603287B1/fr not_active Expired - Fee Related
- 1987-06-01 DK DK280187A patent/DK280187A/da not_active Application Discontinuation
- 1987-06-01 BE BE8700605A patent/BE1002130A3/fr not_active IP Right Cessation
- 1987-06-01 IT IT8705187A patent/IT1207805B/it active
- 1987-06-02 DE DE19873718476 patent/DE3718476A1/de not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| GB2191200A (en) | 1987-12-09 |
| ES2004734A6 (es) | 1989-02-01 |
| BE1002130A3 (fr) | 1990-07-24 |
| IT1207805B (it) | 1989-06-01 |
| FR2603287A1 (fr) | 1988-03-04 |
| IT8705187A0 (it) | 1987-06-01 |
| DK280187A (da) | 1987-12-03 |
| DK280187D0 (da) | 1987-06-01 |
| GB8613315D0 (en) | 1986-07-09 |
| DE3718476A1 (de) | 1987-12-03 |
| FR2603287B1 (fr) | 1991-02-08 |
| GB2191200B (en) | 1990-07-11 |
| CH674939A5 (da) | 1990-08-15 |
| NL8701254A (nl) | 1988-01-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU627694B2 (en) | Conjugates of cytokines with immunoglobulins | |
| JP3589459B2 (ja) | 生物応答調節物質の新規な抗体運送システム | |
| JP2518911B2 (ja) | ｃ―ｆｍｓ癌原遺伝子の過剰発現によって特徴づけられた癌の処置用組成物および方法 | |
| JPH03501208A (ja) | 細胞毒性結合体 | |
| WO1990006952A1 (en) | Chemically modified granulocyte colony stimulating factor | |
| WO1996028475A1 (fr) | Facteur de croissance des hepatocytes modifie a l'aide de polyethylene glycol | |
| KR20040071212A (ko) | 생물학적 활성 과립구 콜로니 자극 인자의 정제 및(또는)단리 방법 | |
| EP0325270A2 (en) | Anticancer conjugates | |
| EP0276551B1 (en) | Colony-stimulating factor and method for preparation thereof | |
| EP0717753B1 (en) | Ribosome inactivating proteins extracted from seeds of saponaria ocymoides and vaccaria pyramidata, their preparation and immunotoxins containing them | |
| JPS62292800A (ja) | 生物活性を有する金属タンパク質複合体およびその製法 | |
| EP0328132B1 (en) | Therapeutic agent for thrombocytopenia | |
| CA2058464A1 (en) | Induction of tolerance with modified immunogens | |
| PT866861E (pt) | Clonagem molecular e caracterizacao de moleculas relacionadas com relaxina e com a familia dos ligandos da insulina | |
| US7902146B2 (en) | Therapeutic, prophylactic, and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties | |
| JPH04327600A (ja) | ペプチド複合体およびそれを有効成分とする医薬 | |
| JPH01287097A (ja) | 抗腫瘍性蛋白質 | |
| CA2292757C (en) | Therapeutic, prophylactic and diagnostic agent for cancer, useful for characterizing cancer cells with individual properties | |
| JPH03236400A (ja) | 化学修飾ポリペプチド及びその用途 | |
| JPS6089433A (ja) | 制癌作用物質複合体の製造法 | |
| JPH1080281A (ja) | 新規蛋白質及びその製造方法 | |
| JPS6272623A (ja) | 悪性腫瘍等の治療方法 | |
| KR20010112290A (ko) | 약리학적 활성 폴리펩티드-당 결합체 | |
| WO1994002174A1 (en) | Immunocomplex | |
| JPH04293482A (ja) | スーパーオキシドジスムターゼとＦｃの複合体 |